Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype

References

• Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349(9058):1050–1053.
   PubMed Web of Science ®Google Scholar
• Lietz K, John R, Burke EA, et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation. 2001;72(2):277–283.
   PubMed Web of Science ®Google Scholar
• Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115(10):1428–1434.
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102.
   PubMed Web of Science ®Google Scholar
• Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13–22.
   PubMed Web of Science ®Google Scholar
• Nishikido T, Oyama JI, Nagatomo D, et al. A reduction of BMI predicts the risk of rehospitalization and cardiac death in non-obese patients with heart failure. Int J Cardiol. 2019;276:166–170.
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235(5):479–785.
   PubMed Web of Science ®Google Scholar
• Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19(12):1814–1822.
   PubMed Web of Science ®Google Scholar
• Doehner W, Rauchhaus M, Florea VG, et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 2001;141(5):792–799.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;106(24):3073–3078.
   PubMed Web of Science ®Google Scholar
• Ayoub KF, Pothineni NVK, Rutland J, et al. Immunity, inflammation, and oxidative stress in heart failure: emerging molecular targets. Cardiovasc Drugs Ther. 2017;31(5-6):593–608.
   PubMed Web of Science ®Google Scholar
• von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999;99(22):2934–2941.
   PubMed Web of Science ®Google Scholar
• Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002;8(3):132–140.
   PubMedGoogle Scholar
• Siegismund CS, Escher F, Lassner D, et al. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail. 2018;20(4):751–757.
   PubMed Web of Science ®Google Scholar
• Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25–30.
   PubMedGoogle Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008;83(3):297–303.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Ando Y, Holmgren G, et al. Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient's survival. Transplant Int. 1998;11(s1):S160–S163.
   PubMedGoogle Scholar
• Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–2604.
   PubMed Web of Science ®Google Scholar
• Tabtabai SV, Steiner J, Stone K, et al. Modified BMI does not predict adverse outcomes in patients with cardiac amyloid undergoing heart transplantation: a report from ICCAT (International Consortium for Cardiac Amyloid Transplantation) [Abstract]. JACC 2015.
   Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–183.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Conceicao IM, Karayal ON, et al. Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther. 2014;3(2):101–112.
   PubMedGoogle Scholar
• Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–1433.
   PubMed Web of Science ®Google Scholar
• Doehner W, Jankowska EA, Springer J, et al. Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. Int J Cardiol. 2016;213:15–19.
   PubMed Web of Science ®Google Scholar
• Wei L, Fahey T, Struthers AD, et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009;63(9):1327–1333.
   PubMed Web of Science ®Google Scholar
• Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–2309.
   PubMed Web of Science ®Google Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–1771.
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Kober L, Jhund PS, et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20(3):514–522.
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Anker SD. Plasma concentrations of bacterial lipopolysaccharide: a marker of infection or inflammation? J Am Coll Cardiol. 2000;36(2):656–657.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–1491.
   PubMed Web of Science ®Google Scholar